Specify a stock or a cryptocurrency in the search bar to get a summary
Oncozenge AB
ONCOZOncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden. Address: Gustavslundsvägen 34, Bromma, Sweden, 167 51
Analytics
WallStreet Target Price
27.03 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ONCOZ
Dividend Analytics ONCOZ
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ONCOZ
Stock Valuation ONCOZ
Financials ONCOZ
Results | 2019 | Dynamics |